Back to top
more

BellRing Brands (BRBR)

(Delayed Data from NYSE)

$49.67 USD

49.67
1,540,553

-1.56 (-3.05%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $49.64 -0.03 (-0.06%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

Here's Why You Should Hold on to Hill-Rom (HRC) for Now

Investors are optimistic about Hill-Rom (HRC) owing to strategic buyouts and continued expansion efforts in the digital health space.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Why BellRing Brands (BRBR) Could Beat Earnings Estimates Again

BellRing Brands (BRBR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is BellRing Brands (BRBR) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now

Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.

Here's Why You Should Retain CVS Health (CVS) Stock For Now

Investors are optimistic about CVS Health (CVS) on growth in the company's specialty digital solutions and a bullish 2021 outlook.

Bio Rad (BIO) Global Growth Strong, Expenses Continue to Rise

Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.

Cardiovascular Systems (CSII) Treats 1st Patient With ViperCross

Cardiovascular Systems' (CSII) ViperCross offers the correct balance of support and flexibility to navigate tortuous anatomy and cross challenging lesions.

Quest Diagnostics' (DGX) Base Volumes Rise, Testing Recovers

Contributions from new hospital lab management contracts as well as people returning to the healthcare system aid Quest Diagnostics (DGX).

Medtronic (MDT) Gets CE Mark for Radial Artery Access Portfolio

Medtronic's (MDT) Rist Radial Access Catheters are indicated for the introduction of interventional devices into the peripheral, coronary and neuro vasculature.

NEOGEN (NEOG) Inks Genomic Selection Deal With Hendrix

Hendrix Genetics with the help of NEOGEN's (NEOG) Genomics will be able to genotype the elite animals in the population.

Here's Why You Should Invest in Quest Diagnostics (DGX) Now

Investors are optimistic about Quest Diagnostics (DGX) backed by its strong second-quarter performance and recovery in the base testing business.

New Strong Buy Stocks for September 29th

BRBR, CNHI, DLA, FNF, and RM have been added to the Zacks Rank #1 (Strong Buy) List on September 29, 2021.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

Investors are optimistic about Medtronic (MDT) owing to new product flow and strong market share gain across the company's businesses.

Medtronic (MDT) Hugo RAS System Used for 1st Clinical Procedure

Medtronic's (MDT) Hugo RAS system is a modular, multi-quadrant platform intended for a broad range of soft-tissue procedures.

IDEXX (IDXX) CAG Placement Grows Globally Amid Cost Woes

IDEXX's (IDXX) global reference lab revenues are growing organically, reflecting growth in the United States and the international markets.

Here's Why You Should Add Alcon Stock (ALC) to Your Portfolio

Investors continue to be optimistic about Alcon (ALC) backed by robust second-quarter performance and raised 2021 outlook.

NuVasive (NUVA) Expands Training Opportunities With New Center

NuVasive's (NUVA) East Coast Experience Center reflects the company's commitment to provide best quality surgeon education and training to enhance the standard of patient care in spine surgery.

CVS Health (CVS) Retail Business Grows Despite Cost Pressure

CVS Health's (CVS) retail business sees solid rebound in front-store sales with strength across all categories.

SmileDirectClub (SDC) to Boost Europe Presence, Enter France

SmileDirectClub (SDC) since its foray into Europe in 2019 has been seeing remarkable market penetration of its oral care products.

Neogen (NEOG) Q1 Earnings Top Estimates, Gross Margin Up

Strong segmental performance and contributions from new acquisitions and product launches drove Neogen's (NEOG) revenues in the first quarter of fiscal 2022.

Medtronic (MDT) Starts Pediatric Trial for Scoliosis Treatment

Medtronic's (MDT) BRAIVE IDE study will assess the safety and efficacy of growth modulation system in correcting the spine's curve in patients with juvenile or adolescent idiopathic scoliosis.

Boston Scientific (BSX) Strategic Buyouts Aid Amid Cost Woes

Boston Scientific (BSX) is optimistic about its recent deal to acquire Israel-based Lumenis that develops and commercializes energy-based medical solutions.

New Strong Buy Stocks for September 22nd

BRBR, CNHI, MCFT, CC, and UFI have been added to the Zacks Rank #1 (Strong Buy) List on September 22, 2021.

Here's Why You Should Invest in Align Technology (ALGN) Now

Investors continue to be optimistic about Align Technology (ALGN) on robust second-quarter 2021 performance and raised guidance.